Business Context and Reporting Period
This Form 6-K filing by Innate Pharma S.A., a foreign private issuer, was submitted on January 7, 2026. The report serves to disseminate a press release dated January 7, 2026, to U.S. investors. The registrant is headquartered in Marseille, France, and files annual reports under Form 20-F.
Financial Metrics
The provided filing text contains only the cover page and exhibit index. It does not include the content of the press release (Exhibit 99.1) or any financial statements. Consequently, there is no data available regarding revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The filing text does not provide specific details on material changes versus prior periods. The nature of the update is limited to the distribution of a press release, the content of which is not included in the source text.
Guidance, Outlook, and Risks
Management commentary, future guidance, risk factors, contingencies, and unusual items are not described in the provided text. The filing references a press release but does not contain its substance.
Key Facts for Investor Verification
- The filing is a Form 6-K dated January 7, 2026, signed by CEO Jonathan Dickinson.
- The report references a press release (Exhibit 99.1) but does not include the text of that release.
- No financial figures or operational updates are present in the provided source text.
- Investors must locate and review the full text of the January 7, 2026 press release to obtain material information.